Macrophages play important roles in host
defense mechanisms. In the brain, besides microglial
cells, meningeal macrophages are present. However, the
pathobiological characteristics of meningeal
macrophages in rats remain to be investigated. In normal
meninx, immunohistochemically, macrophages reacting
to CD163 (macrophage scavenger receptor) and major
histocompatibility complex (MHC) class II-expressing
cells (involving activated macrophages or dendritic
cells) were sporadically seen without age-dependent
changes. Injection of lipoplysaccharide (LPS) (5 μg;
Escherichia coli) into the cerebrum increased the
number of anti-CD68-positive macrophages (with
greater phagocytic activity) in the meninx, with a peak at
12 h during observation period until 48 h; MHC class IIexpressing
cells showed a gradual increase in number
from 3 h after injection; however, anti-CD163-positive macrophages did not show significant change. In in vitro
studies, LPS (0, 0.02, 0.05, 0.5, 5, 50 and 100 μg/ml)
was added to KMY-1 or KMY-2 cells, both of which had
been established from a rat malignant meningioma.
KMY-1 originally reacted to CD163, but LPS addition at
0.5 μg/ml and greater concentrations decreased the anti-
CD163-positive cell number and instead increased the
anti-CD68-positive cell number. LPS-treated KMY-2
increased the anti-CD163-positive cell number at 0.05
and 0.5 μg/ml. By RT-PCR methods, LPS (0, 0.5, 5, 50,
and 100 μg/ml)-treated KMY-1 and KMY-2 showed an
increase in mRNA of monocyte chemoattractant protein-
1 (MCP-1, a chemokine), and LPS-treated KMY-2
increased mRNA of nerve growth factor (NGF, an
immunological effecter). Collectively, under LPS
treatment, macrophages with heterogeneous functions appear in rat meninx; rat meninx-forming cells may be
involved in pathogenesis of meningeal inflammation by
expressing different immunophenotypes and by
producing regulatory proinflammatory factors such as
MCP-1 and NGF